KR20190068575A - 안구 표면 항상성의 확립, 회복 및 보존 방법 - Google Patents

안구 표면 항상성의 확립, 회복 및 보존 방법 Download PDF

Info

Publication number
KR20190068575A
KR20190068575A KR1020197013278A KR20197013278A KR20190068575A KR 20190068575 A KR20190068575 A KR 20190068575A KR 1020197013278 A KR1020197013278 A KR 1020197013278A KR 20197013278 A KR20197013278 A KR 20197013278A KR 20190068575 A KR20190068575 A KR 20190068575A
Authority
KR
South Korea
Prior art keywords
fluid
eye
preservative
administered
surgery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197013278A
Other languages
English (en)
Korean (ko)
Inventor
볼프강 게오르크 콘라트 물러-리르하임
제텐 귀스베르트-보토 반
Original Assignee
이콤 메디칼 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60766004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20190068575(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 이콤 메디칼 게엠베하 filed Critical 이콤 메디칼 게엠베하
Publication of KR20190068575A publication Critical patent/KR20190068575A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197013278A 2016-10-14 2017-10-02 안구 표면 항상성의 확립, 회복 및 보존 방법 Ceased KR20190068575A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662408559P 2016-10-14 2016-10-14
US62/408,559 2016-10-14
US201762516911P 2017-06-08 2017-06-08
US62/516,911 2017-06-08
PCT/IB2017/001364 WO2018069763A1 (en) 2016-10-14 2017-10-02 Method for establishing, restoring, and preserving homeostasis of the ocular surface

Publications (1)

Publication Number Publication Date
KR20190068575A true KR20190068575A (ko) 2019-06-18

Family

ID=60766004

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197013278A Ceased KR20190068575A (ko) 2016-10-14 2017-10-02 안구 표면 항상성의 확립, 회복 및 보존 방법

Country Status (8)

Country Link
US (1) US20190240251A1 (enExample)
EP (2) EP3871682A1 (enExample)
JP (3) JP2019532105A (enExample)
KR (1) KR20190068575A (enExample)
ES (1) ES2909998T3 (enExample)
HU (1) HUE058672T2 (enExample)
PL (1) PL3525799T3 (enExample)
WO (1) WO2018069763A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190068575A (ko) 2016-10-14 2019-06-18 이콤 메디칼 게엠베하 안구 표면 항상성의 확립, 회복 및 보존 방법
WO2019202017A1 (en) * 2018-04-18 2019-10-24 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
CN112714644B (zh) * 2018-09-20 2024-03-29 香港科技大学 滴眼剂组合物
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
WO2021250462A1 (en) * 2020-06-12 2021-12-16 I. Com Medical Gmbh High molecular weight hyaluronic acid for use in the treatment of corneal nerve damage or loss
US20230233687A1 (en) * 2020-06-21 2023-07-27 i.com medical GmbH Hyaluronic acid-based formulations for treatment and prevention of ocular hypertension and glaucoma
EP4536189A1 (en) * 2022-06-08 2025-04-16 The Schepens Eye Research Institute, Inc. Methods for treating dry eye disease
EP4591860A1 (en) * 2024-01-23 2025-07-30 FB Vision S.p.A. Ophthalmic pharmaceutical composition for the prevention and treatment of dry eye syndrome

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1263606A (en) * 1985-05-29 1989-12-05 Jeffrey P. Gilbard Non-toxic opthalmic preparations
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
JP3050898B2 (ja) * 1990-07-06 2000-06-12 千寿製薬株式会社 水性医薬製剤
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
SE9700827D0 (sv) * 1997-03-07 1997-03-07 Pharmacia & Upjohn Ab Ophthalmic composition
ES2206363T3 (es) * 2000-04-07 2004-05-16 Laboratoire Medidom S.A. Formulaciones oftalmicas a base de ciclosporina, de acido hialuronico y de polisorbato.
US6528464B1 (en) * 2001-08-17 2003-03-04 Bausch & Lomb Incorporated Composition and method for inhibiting uptake of biguanide antimicrobials by hydrogels
JP3779200B2 (ja) * 2001-11-28 2006-05-24 電気化学工業株式会社 ヒアルロン酸及び／又はその塩の水溶液の安定化組成物
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
CN1671400A (zh) * 2002-07-03 2005-09-21 派瑞克科学公司 透明质酸组合物以及使用方法
DE10360425A1 (de) 2003-12-19 2005-07-28 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung
KR101554834B1 (ko) * 2005-10-12 2015-09-21 세이가가쿠 고교 가부시키가이샤 점막에 적용하는 작용제 및 그것의 제조 방법
JP2008255061A (ja) * 2007-04-06 2008-10-23 Shiseido Co Ltd 可溶性架橋ヒアルロン酸含有眼用組成物
WO2009025763A2 (en) * 2007-08-16 2009-02-26 Schepens Eye Research Institute Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
NZ602479A (en) * 2008-05-15 2013-05-31 R Tech Ueno Ltd Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
JP5595206B2 (ja) * 2009-09-30 2014-09-24 ロート製薬株式会社 眼科用液体組成物
US8283463B2 (en) * 2010-02-09 2012-10-09 Bausch & Lomb Incorporated Sterile hyaluronic acid solutions
DK2598526T3 (en) * 2010-07-29 2018-11-19 Eleven Biotherapeutics Inc CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS
CN103096929A (zh) * 2010-09-10 2013-05-08 参天制药株式会社 以组合p2y2受体激动剂和透明质酸或其盐为特征的干眼症治疗剂、干眼症的治疗方法、及干眼症治疗剂的应用
US20170360013A1 (en) * 2014-12-02 2017-12-21 Regeneron Pharmaceuticals, Inc. Animal model for dry eye and methods of use of such animals
SG10201901426WA (en) * 2015-03-06 2019-03-28 Santen Pharmaceutical Co Ltd Ophthalmic composition
US20170014339A1 (en) 2015-07-17 2017-01-19 i.com medical GmbH Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute
KR20190068575A (ko) 2016-10-14 2019-06-18 이콤 메디칼 게엠베하 안구 표면 항상성의 확립, 회복 및 보존 방법
WO2019202017A1 (en) * 2018-04-18 2019-10-24 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
US12268706B2 (en) * 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain

Also Published As

Publication number Publication date
JP2019532105A (ja) 2019-11-07
ES2909998T3 (es) 2022-05-11
US20190240251A1 (en) 2019-08-08
EP3525799A1 (en) 2019-08-21
EP3525799B1 (en) 2022-01-26
HUE058672T2 (hu) 2022-09-28
WO2018069763A1 (en) 2018-04-19
JP2025029084A (ja) 2025-03-05
EP3871682A1 (en) 2021-09-01
JP2022153583A (ja) 2022-10-12
PL3525799T3 (pl) 2022-05-16

Similar Documents

Publication Publication Date Title
KR20190068575A (ko) 안구 표면 항상성의 확립, 회복 및 보존 방법
AU2008289552B2 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
JP2020502197A (ja) ドライアイ疾患の治療のための眼科用組成物
JP2025026942A (ja) 上皮の生存と体表面の再構成を高めるための高分子量ヒアルロン酸
US20250276004A1 (en) High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
CN113577097A (zh) 高弹性透明质酸组合物及其使用方法
JP2023530189A (ja) 高眼圧症および緑内障の治療および予防のためのヒアルロン酸に基づく製剤
US12268706B2 (en) Hyaluronic acid for relief of idiopathic ocular pain
JP2023530286A (ja) 角膜神経損傷又は喪失の治療に使用する高分子量ヒアルロン酸
RU2679319C1 (ru) Гелеобразная искусственная слеза с антисептическим и репаративным действием
EA046057B1 (ru) Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности
AU2014227534B2 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
EA050162B1 (ru) Высокомолекулярная гиалуроновая кислота для улучшения выживания эпителия и восстановления поверхностей тела
CA2640986A1 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
JP2020535117A (ja) 眼疾患を治療するためのアディポネクチンペプチド模倣薬

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190509

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200928

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220701

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230425

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220701

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230425

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230102

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200928

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20231005

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230925

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20230425

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230102

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220701

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200928

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20240306

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20231005

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20230425

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2024101000552

Request date: 20240306

J301 Trial decision

Free format text: TRIAL NUMBER: 2024101000552; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20240306

Effective date: 20241231

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20241231

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20240306

Decision date: 20241231

Appeal identifier: 2024101000552